Key Takeaways
- CMS approved a final 2.48% Medicare Advantage payment rate for 2027, dramatically higher than the 0.09% initially proposed in January.
- Humana (HUM) shares skyrocketed 12% in after-hours trading, with UnitedHealth (UNH) and CVS Health (CVS) climbing more than 6% in premarket sessions.
- The approved rate represents approximately $13 billion in additional Medicare Advantage funding for private insurers in 2027.
- Other managed care stocks joined the rally, including Molina Healthcare (MOH) gaining 7% and Centene (CNC) advancing 4%.
- Mizuho’s Jared Holz described the rate as “certainly better than the government’s initial rate decision,” while cautioning it isn’t extraordinary in isolation.
Humana (HUM) shares opened approximately 11% higher on Tuesday morning, responding to the previous evening’s release of finalized 2027 Medicare Advantage reimbursement rates.
The approved 2.48% rate marks a dramatic improvement from the preliminary 0.09% figure floated in January, which shocked industry participants and triggered a selloff in insurance stocks.
The CMS decision translates into over $13 billion in incremental Medicare Advantage revenue flowing to private health plans from federal coffers throughout 2027.
UnitedHealth (UNH) and CVS Health (CVS), which owns Aetna, each posted premarket gains exceeding 6% on Tuesday. Elevance Health (ELV) advanced approximately 5%. The positive momentum extended to hospital operators and managed care providers, with Molina Healthcare (MOH) climbing 7% and Centene (CNC) adding 4%.
The share price surge follows intensive advocacy efforts by insurers and industry associations, who contended the January proposal failed to account for escalating medical expenses. The Better Medicare Alliance characterized the initial near-zero rate as an effective “reduction,” noting medical cost inflation trends between 7% and 9% annually.
Key Modifications in the Final Decision
CMS implemented several technical adjustments beyond the headline rate figure. Beginning in 2027, the agency will eliminate diagnosis information from unlinked chart review records in risk score calculations, while creating an exception for beneficiaries transferring between Medicare Advantage carriers.
Officials indicated this modification will disproportionately affect plans that depend significantly on chart reviews for documenting patient conditions and securing enhanced reimbursements. CMS additionally revised the Part D risk adjustment framework to incorporate Inflation Reduction Act provisions.
CMS Administrator Dr. Mehmet Oz stated the revisions seek to maintain “coverage affordable” while ensuring enrollees receive “real value from their plans.”
Analysts on Wall Street had adopted a conservative stance before Monday’s disclosure. TD Cowen’s Ryan Langston had projected a more moderate increase in the 1% to 1.5% range. The 2.48% result surpassed these projections, although Mizuho’s Jared Holz offered measured commentary: “We do not believe a Medicare rate increase of 2.5% is so awesome in a vacuum, but is certainly better than the government’s initial rate decision.”
Holz noted there is now “a chance for margins to expand next year, provided the Companies continue to trim benefits and align costs with revenue.”
Why This Rate Matters
Medicare Advantage serves approximately 35 million Americans and has expanded consistently to exceed traditional fee-for-service Medicare enrollment. The finalized rate determines the distribution of more than half a trillion dollars through private insurance plans annually, establishing it as among the most scrutinized metrics in the health coverage industry.
The rate encompasses multiple variables including underlying expense growth, 2026 Star Ratings that determine quality incentive payments, and risk adjustment methodology refinements. CMS verified it will maintain the 2024 Medicare Advantage risk adjustment model for 2027.
Bipartisan concerns about Medicare Advantage expenditure control had injected uncertainty into the rate-setting process. Lawmakers from both parties have questioned insurer documentation practices that can generate elevated payments for patients with more extensive recorded diagnoses. The Biden administration’s CMS had already begun restricting those payments, and the January proposal under the Trump administration indicated that oversight would persist.
